Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo, Thomas P C and Kip, Anke E and Younis, Brima M and Ellis, Sally J and Alves, Fabiana and Beijnen, Jos H and Njenga, Simon and Kirigi, George and Hailu, Asrat and Olobo, Joseph and Musa, Ahmed M and Balasegaram, Manica and Wasunna, Monique and Karlsson, Mats O and Khalil, Eltahir A G (2017) Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. The Journal of antimicrobial chemotherapy, 72 (11). pp. 3131-3140. ISSN 1460-2091

Full text not available from this repository.

Abstract

Background Low efficacy of miltefosine in the treatment of visceral leishmaniasis was recently observed in Eastern Africa. Objectives To describe the pharmacokinetics and establish a pharmacokinetic/pharmacodynamic relationship for miltefosine in Eastern African patients with visceral leishmaniasis, using a time-to-event approach to model relapse of disease. Methods Miltefosine plasma concentrations from 95 patients (48 monotherapy versus 47 combination therapy) were included in the population pharmacokinetic model using non-linear mixed effects modelling. Subsequently a time-to-event model was developed to model the time of clinical relapse. Various summary pharmacokinetic parameters (various AUCs, Time > EC50, Time > EC90), normalized within each treatment arm to allow simultaneous analysis, were evaluated as relapse hazard-changing covariates. Results A two-compartment population model with first-order absorption fitted the miltefosine pharmacokinetic data adequately. Relative bioavailability was reduced (-74%, relative standard error 4.7%) during the first week of treatment of the monotherapy arm but only the first day of the shorter combination regimen. Time to the relapse of infection could be described using a constant baseline hazard (baseline 1.8 relapses/year, relative standard error 72.7%). Miltefosine Time > EC90 improved the model significantly when added in a maximum effect function on the baseline hazard (half maximal effect with Time > EC90 6.97 days for monotherapy). Conclusions Miltefosine drug exposure was found to be decreased in Eastern African patients with visceral leishmaniasis, due to a (transient) initial lower bioavailability. Relapse hazard was inversely linked to miltefosine exposure. Significantly lower miltefosine exposure was observed in children compared with adults, further urging the need for implementation of dose adaptations for children.

Item Type: Article
Subjects: Q Science > QR Microbiology
Depositing User: Unnamed user with email almegdadsharaf@gmail.com
Date Deposited: 14 Jan 2018 17:31
Last Modified: 14 Jan 2018 17:31
URI: http://search.srh.edu.sd/id/eprint/2596

Actions (login required)

View Item View Item